PHILEMON: a step closer to using MRD to guide treatment decisions in mantle cell lymphoma (MCL)?
Using computational algorithms to predict the response of MDS patients to hypomethylating agents
CTL019 in pediatric and young adult relapsed/refractory acute lymphoblastic leukemia (ALL) patients
Real world implications of the cost of myeloma treatment: it’s not just the cost of the drugs
Pomalidomide with dexamethasone in relapsed/refractory multiple myeloma with renal impairment
Temsirolimus with BERT for the treatment of relapsed mantle cell and follicular lymphoma